RCS - Oxford Biomedica PLC - OXB Lentiviral Vectors Used in Gene Therapy Trial

Oxford BioMedicaAnnouncement

20/02/2025 13:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250220:nRST9109Xa&default-theme=true

RNS Number : 9109X  Oxford Biomedica PLC  20 February 2025

 

 

 

OXB's lentiviral vector manufacturing technology to support Boehringer
Ingelheim's newly initiated Phase I/II trial of first-in-class gene therapy
for cystic fibrosis

Commencement of LENTICLAIR™ 1 trial, utilising  OXB lentiviral vectors;
builds on long term collaboration with Boehringer Ingelheim

Oxford, UK - 20 February 2025: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces that its
proprietary lentiviral vector manufacturing technology will be used in
Boehringer Ingelheim's newly initiated
(https://www.boehringer-ingelheim.com/partnering/human-health-partnering/developing-novel-gene-therapy-cystic-fibrosis-patients)
LENTICLAIR™ 1 trial. The Phase I/II study is evaluating BI 3720931, a novel,
first-in-class, inhaled gene therapy for the treatment of cystic fibrosis
(CF).

 

With three decades of expertise in viral vector development and manufacturing,
OXB will support the development of this potential treatment for CF, a genetic
condition caused by mutations in the CFTR gene that affects more than 100,000
people worldwide. While CFTR modulators have provided treatment options for
some patients, there remains a significant unmet need for 10-15% of people
with CF due to mutation type or modulator intolerance.

 

BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy
designed to address this need through a novel approach of inserting a
functional copy of the CFTR gene in the DNA of airway epithelial cells.

 

This trial builds on the successful collaboration initiated in August 2018
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1139884)
with Boehringer Ingelheim. OXB's ongoing role in this programme highlights its
reputation as a trusted CDMO and its commitment to advancing pioneering gene
therapies that address significant unmet needs.

 

Frank Mathias, Chief Executive Officer of OXB, said: "We are delighted that
Boehringer Ingelheim is using OXB's proprietary lentiviral vector
manufacturing technology for the clinical development of their CF gene
therapy. This programme has the potential to transform the lives of patients
living with CF and exemplifies OXB's commitment to supporting cutting-edge
cell and gene therapies. We look forward to playing a key role in its
progression."

 

 

-Ends-

 

Enquiries:

 

OXB:

Sebastien Ribault, Chief Business Officer - T: +44 (0) 1865 783 000 / E:
partnering@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life-changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities span
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
TetraVecta™ system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

About Boehringer Ingelheim

 

Boehringer Ingelheim is a biopharmaceutical company active in both human and
animal health. As one of the industry's top investors in Research and
Development, the company focuses on developing innovative therapies in areas
of high unmet medical need. Independent since its foundation in 1885,
Boehringer takes a long-term perspective, embedding sustainability along the
entire value chain. More than 53,500 employees serve over 130 markets to build
a healthier, more sustainable, and equitable tomorrow. Learn more at
https://www.boehringer-ingelheim.com (https://www.boehringer-ingelheim.com) .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEADAEADASEFA